ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 570,20
-0,77%
Dow Jones
38 834,86
0,15%
DAX
18 067,91
-0,31%
Brent Oil
84,695
-0,11%
Bitcoin
64 852,56
-0,44%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Gossamer Bio Inc (GOSS)

  7. Gossamer Bio Inc (GOSS) Actualités

GOSS

Gossamer Bio (GOSS)

Gossamer Bio Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:GOSS
DateHeureSourceTitreSymboleSociété
10/06/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GOSSGossamer Bio Inc
07/06/202422h30Business WireGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GOSSGossamer Bio Inc
07/06/202403h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GOSSGossamer Bio Inc
14/05/202422h01Business WireGossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International ConferenceNASDAQ:GOSSGossamer Bio Inc
07/05/202422h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GOSSGossamer Bio Inc
07/05/202422h01Business WireGossamer Bio Announces First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:GOSSGossamer Bio Inc
06/05/202413h30Business WireGossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other IndicationsNASDAQ:GOSSGossamer Bio Inc
03/05/202414h02Business WireGossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory MedicineNASDAQ:GOSSGossamer Bio Inc
12/03/202412h31Business WireGossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of DirectorsNASDAQ:GOSSGossamer Bio Inc
05/03/202413h37Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:GOSSGossamer Bio Inc
05/03/202413h32Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:GOSSGossamer Bio Inc
05/03/202413h31Business WireGossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateNASDAQ:GOSSGossamer Bio Inc
13/12/202322h01Business WireGossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023NASDAQ:GOSSGossamer Bio Inc
05/12/202323h09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:GOSSGossamer Bio Inc
05/12/202313h01Business WireGossamer Bio Appoints Bob Smith as Chief Commercial OfficerNASDAQ:GOSSGossamer Bio Inc
29/11/202313h01Business WireGossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of DirectorsNASDAQ:GOSSGossamer Bio Inc
09/11/202313h31Business WireGossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:GOSSGossamer Bio Inc
03/10/202322h08Business WireGossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical AffairsNASDAQ:GOSSGossamer Bio Inc
07/09/202313h44Business WireGossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023NASDAQ:GOSSGossamer Bio Inc
29/08/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GOSSGossamer Bio Inc
28/08/202322h29Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GOSSGossamer Bio Inc
21/08/202322h01Edgar (US Regulatory)Form DEL AM - Delaying amendmentNASDAQ:GOSSGossamer Bio Inc
18/08/202314h41Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:GOSSGossamer Bio Inc
18/08/202314h38Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:GOSSGossamer Bio Inc
17/08/202322h01Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:GOSSGossamer Bio Inc
08/08/202322h01Business WireGossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:GOSSGossamer Bio Inc
07/08/202322h44Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:GOSSGossamer Bio Inc
28/07/202321h46Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:GOSSGossamer Bio Inc
24/07/202322h16Business WireGossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE ResultsNASDAQ:GOSSGossamer Bio Inc
20/07/202313h56Business WireGossamer Bio Announces $212 Million Private Placement FinancingNASDAQ:GOSSGossamer Bio Inc
 Showing the most relevant articles for your search:NASDAQ:GOSS

Dernières Valeurs Consultées

BOV
PEAB3
PAR AL BAHIA ON
NASDAQ
FITBI
Fifth Third Bancorp
BIT
I10005
IT0005589988 20240902 24.5
EU
SSINP
Euronext S ING 070322 PR...
LSE
72XJ
07jun2036c
EU
0073T
0073T
NASDAQI
HX3020PI
OMX Helsinki Financial S...
LSE
RTT
RCM Technology
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés